CAS 936091-26-8

Fedratinib

Description:

Fedratinib is a small molecule drug primarily used in the treatment of certain types of blood cancers, particularly myelofibrosis. It functions as a selective inhibitor of the Janus kinase 2 (JAK2) enzyme, which plays a crucial role in the signaling pathways that regulate blood cell production and immune responses. The chemical formula of Fedratinib reflects its complex structure, which includes multiple functional groups that contribute to its pharmacological activity. It is characterized by its ability to modulate hematopoiesis and reduce splenomegaly associated with myelofibrosis. Fedratinib is administered orally and has a specific pharmacokinetic profile, including absorption, distribution, metabolism, and excretion characteristics that influence its therapeutic efficacy and safety. Common side effects may include gastrointestinal disturbances and potential impacts on liver function, necessitating monitoring during treatment. Overall, Fedratinib represents a targeted therapeutic approach in oncology, highlighting the importance of molecular specificity in drug design.

Formula: C₂₇H₃₆N₆O₃S

InChI: InChI=1S/C27H36N6O3S/c1-20-19-28-26(30-21-10-12-23(13-11-21)36-17-16-33-14-5-6-15-33)31-25(20)29-22-8-7-9-24(18-22)37(34,35)32-27(2,3)4/h7-13,18-19,32H,5-6,14-17H2,1-4H3,(H2,28,29,30,31)

InChI key: InChIKey=JOOXLOJCABQBSG-UHFFFAOYSA-N

SMILES: S(NC(C)(C)C)(=O)(=O)C1=CC(NC2=NC(NC3=CC=C(OCCN4CCCC4)C=C3)=NC=C2C)=CC=C1

Synonyms:

• Benzenesulfonamide, N-(1,1-dimethylethyl)-3-[[5-methyl-2-[[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]amino]-4-pyrimidinyl]amino]-
• Fedratinib
• Inrebic
• Sar 302503
• TG101348 HCl
• Tg 101348
• Tg 10138
• Tg101348
• N-(1,1-Dimethylethyl)-3-[[5-methyl-2-[[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]amino]-4-pyrimidinyl]amino]benzenesulfonamide
• N-(1,1-Dimethylethyl)-3-[[5-methyl-2-[[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]amino]-4-pyrimidinyl]amino]benzenesulfonamide TG 101348
• Fedratinib (SAR302503, TG101348)
• TG101348/TG-101348
• Fedratinib (TG101348)
• SAR302503/TG101348
• TG101348 (SAR302503)
• N-TERT-BUTYL-3-(5-METHYL-2-(4-(2-(PYRROLIDIN-1-YL)ETHOXY)PHENYLAMINO)PYRIMIDIN-4-YLAMINO)BENZENESULFONAMIDE
• N-(1,1-Dimethylethyl)-3-[[5-methyl-2-[[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]amino]-4-pyrimidinyl
• Fedratinib/TG101384

Fedratinib (SAR302503, TG101348)

CAS: 936091-26-8

Formula: C₂₇H₃₆N₆O₃S

Purity: 98%

Color and Shape: Solid

Molecular weight: 524.6781

Ref: IN-DA00GU70

Fedratinib

CAS: 936091-26-8

Fedratinib

Purity: ≥95%

Molecular weight: 524.68g/mol

Ref: 54-BUP15012

Fedratinib

CAS: 936091-26-8

Formula: C₂₇H₃₆N₆O₃S

Molecular weight: 524.68

Ref: 4Z-F-205001

Fedratinib

CAS: 936091-26-8

Fedratinib (TG-101348) (TG101348) is an ATP-competitive inhibitor of JAK2 (IC50: 3 nM) with significantly less potent activity against JAK3.

Formula: C₂₇H₃₆N₆O₃S

Purity: 97.31% - 99.96%

Color and Shape: Solid

Molecular weight: 524.68

Ref: TM-T1995

TG101348

CAS: 936091-26-8

Ref: 7W-GW6453

TG101348

Controlled Product

CAS: 936091-26-8

Applications TG101348 is a selective inhibitor of JAK2 tyrosine kinase. Potent JAK2 inhibitor.
References Rosenthal, A., et al.: Expert Opin. Pharmacotherapy, 15, 1265 (2014); Geyer, H.L., et al.: Hematol., 17, s129 (2012); Zhou, T. et al.: Leukemia, 28, 404 (2014)

Formula: C₂₇H₃₆N₆O₃S

Color and Shape: White To Off-White

Molecular weight: 524.68

Ref: TR-T337905

Fedratinib

CAS: 936091-26-8

JAK2 inhibitor with potential antineoplastic activity

Formula: C₂₇H₃₆N₆O₃S

Purity: Min. 95%

Molecular weight: 524.68 g/mol

Ref: 3D-FD151499